Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya27076ArticlesСтатьиResearch ArticleThe role of nab-paclitaxel in the treatment of patients with metastatic breast cancerРоль nab-паклитаксела в лечении больных метастатическим раком молочной железыFrolovaM AФроловаМ А

канд. мед. наук, ст. науч. сотр. отд-ния клинической фармакологии и химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина

drfrolova@yandex.ruN.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian FederationФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России15092016183VOL 18, NO3 (2016)ТОМ 18, №3 (2016)333709042020Copyright ©; 2016, Consilium MedicumCopyright ©; 2016, ООО "Консилиум Медикум"2016Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/27076

Nab-paclitaxel is nanoparticle albumin-bound paclitaxel. Nab-paclitaxel is free from any kind of solvent and thus reduces the risk of hypersensitivity reactions and other side effects, compared with standard taxanes (paclitaxel, docetaxel). There is no need to use premedication with glucocorticoids and antihistamines during nab-paclitaxel application. In addition, several studies have demonstrated that nab-paclitaxel allows achieving a higher drug concentration in tumor. The article deals with the basic studies of nab-paclitaxel application using different doses and introduction regimens in patients with metastatic breast cancer. We show the algorithm for optimal use of nab-paclitaxel in different clinical cases.

Nab-паклитаксел представляет собой наночастицу паклитаксела, связанную с альбумином. В отличие от стандартных таксанов (паклитаксел, доцетаксел), в составе nab-паклитаксела отсутствуют растворители, что снижает риск развития реакций гиперчувствительности и других побочных явлений. При использовании nab-паклитаксела не требуется проведения премедекации глюкокортикоидами и антигистаминными препаратами. Кроме того, в ряде экспериментов было показано, что применение nab-паклитаксела позволяет создать более высокую концентрацию препарата в опухоли. В статье освещены основные исследования применения nab-паклитаксела в различных дозах и режимах введения при метастатическом раке молочной железы. Приведен возможный алгоритм оптимального режима введения nab-паклитаксела для различных клинических ситуаций.

metastatic breast cancertaxanesnab-paclitaxelметастатический рак молочной железытаксаныnab-паклитакселVan Zuylen I, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001; 19: 125-41.Goldspeil B.R. Guidelines for administration. In: Paclitaxel in Cancer Treatment, Mc Guire W.P and Rowinsky E.K (eds). New York: Marcel Dekker Inc, 1995; p. 175-86.Ten Tije A.J, Verweij J, Loos W.J, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665-85.Weiss R.B, Donehower R.C, Wiernik P.H et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-68.Foote M.A. Using nanotechnology to improve the characteristics of antineoplastic drugs: Improved characteristics of nab - paclitaxel compared with solvent - based paclitaxel. Biotechnol Ann Review 2007; 13: 345-57.Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor - free, albumin - bound paclitaxel, ABI-007, compared with Cremophor - based paclitaxel. Clin Cancer Res 2006; 12: 1317-24.Sparreboom A, van Zuylen L, Brouwer E et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454-57.Hawkins M, Desai N, Soon-Shiong P. Rationale, Preclinical Support, and Clinical Proof - of - Concept for Formulating Water - insoluble Therapeutics as Albumin - stabilized Nanoparticles: Experience with Paclitaxel. AACR 2003. Poster.Price K.S, Castells M.C. Taxol reactions. Allergy Asthma Proc 2002; 23: 205-08.Kloover J.S, den Bakker M.A, Gelderblom H et al. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004; 90: 304-5.Postma T.J, Vermorken J.B, Liefting A.J.M et al. Paclitaxel - induced neuropathy. Ann Oncol 1995; 6: 489-94.Boer H.H, Moorer-van Delft C.M, Muller L.J et al. Ultrastructural neuropathologic effects of taxol on neurons of the freshwater snail Lymnaea stagnalis. J Neurooncol 1995; 25: 49-57.Sahenk Z, Barohn R, New P et al. Taxol neuropathy. Arch Neurol 1994; 51: 72-729.Gradishar W.J, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin - bound paclitaxel compared with polyethylated castor oil - based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-803.Gradishar W.J, Krasnojon D, Cheporov S et al. Significantly longer progression - free survival with nab - paclitaxel compared with docetaxel as first - line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611-9.Gradishar W, Krasnojon D, Cheporov S et al. Phase II Trial of Nab - Paclitaxel Compared With Docetaxel as First - Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival. Clin Breast Cancer 2012; 12 (5): 313-21.Mirtsching B, Cosgriff T, Harker G et al. A phase II study of weekly nanoparticle albumin - bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer 2011; 11: 121-8.Rugo H.S, Barry W.T, Moreno-Aspitia A et al. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab - Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First - Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 2015; 20; 33 (21): 2361-9.Ibrahim N.K, Samuels B, Page R et al. Multicenter phase II trial of ABI-007, an albumin - bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005; 23: 6019-26.Blum J.L, Savin M.A, Edelman G et al. Phase II study of weekly albumin - bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7: 850-6.Aapro M, Tjulandin S, Bhar P, Gradishar W. Weekly nabpaclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post - hoc analysis. Breast 2011; 20: 468-74.Timoney J.P, Mc Guffy D, De Ritis D et al. Incidence of hypersensitivity reactions (HSRs) to albumin - bound paclitaxel (ABI) in patients (pts) with a history of HSR to cremophor - based paclitaxel (P). ASCO Meeting Abstracts 2011; 29: 2566.Munck A. Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new evidence, molecular mechanisms, and physiological significance. Perspect Biol Med 1971; 14: 265-9.Abraxane prescribing information. 2012.Ando M, Watanabe T, Nagata K et al. Efficacy of Docetaxel 60 mg/m2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance. J Clin Oncol 2001; 19 (2): 336-42.Arpino G, Marme F, Cortes J et al. Tailoring the dosing schedule of nab - paclitaxel in metastatic breastcancer according to patient and disease characteristics: Recommendations from a panel of experts. Crit Rev Oncol Hematol 2015 Oct 28. [Epub ahead of print].